---
schema_version: "secwatch.filing_event.v1"
accession: "0001126234-24-000059"
form_type: "8-K"
ticker: null
cik: "0001126234"
company_name: "LUMOS PHARMA, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:37:45.739934+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lumos Pharma positive FDA End-of-Phase 2 meeting; Phase 3 trial plan with placebo control

## Summary
- FDA agreed placebo-controlled design for LUM-201 Phase 3 trial; 2:1 randomization, ~150 patients, 6-month placebo arm.
- Updated Phase 2 data show durable AHV: 12-month 8.2 cm/yr, 24-month 7.3 cm/yr (1.6 mg/kg) vs baseline 4.7 cm/yr.
- Cash $23.2M at March 31, 2024; expected to fund operations through Q3 2024; Q1 net loss $10.4M vs $7.3M year-ago.
- Full 12-month OraGrowtH212 data and additional analyses to be presented at ENDO in Q2 2024.

## SEC filing metadata
- accession: 0001126234-24-000059
- form_type: 8-K
- cik: 0001126234
- company_name: LUMOS PHARMA, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/0001126234-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/lumo-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001126234-24-000059
- JSON: https://secwatch.observer/filing/0001126234-24-000059.json
- Plain text: https://secwatch.observer/filing/0001126234-24-000059.txt

## Key facts
- Earnings Releases
  LUMOS PHARMA, INC. reported the quarter ended March 31, 2024 results: net income $10.4 million.
  - Period: the quarter ended March 31, 2024
  - Net income: $10.4 million
  - Result: reported results
  source text: Net Loss – The net loss for the quarter ended March 31, 2024, was $10.4 million compared to a net loss of $7.3 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/0001126234-24-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.